Inventor · disambiguated record
Mark P. Chao
Also filed as: CHAO MARK P · CHAO MARK PING
22 granted patents·22 pending applications·324 citations·filing 2010–2024
95Inventor score
Files withUNIV LELAND STANFORD JUNIOR29FORTY SEVEN INC8GILEAD SCIENCES INC3CHAO MARK P1JAISWAL SIDDHARTHA1
Top patents by PatentIndex Score
44 records- 0198US11377495B2Markers of acute myeloid leukemia stem cellsUNIV LELAND STANFORD JUNIOR·Filed 2021·Granted Jul 5, 2022·7 cites·7 claims
- 0298US11072655B2Markers of acute myeloid leukemia stem cellsUNIV LELAND STANFORD JUNIOR·Filed 2020·Granted Jul 27, 2021·6 cites·3 claims
- 0398US9493575B2Methods for manipulating phagocytosis mediated by CD47UNIV LELAND STANFORD JUNIOR·Filed 2015·Granted Nov 15, 2016·48 cites·7 claims
- 0498US9399682B2Methods for manipulating phagocytosis mediated by CD47UNIV LELAND STANFORD JUNIOR·Filed 2015·Granted Jul 26, 2016·38 cites·7 claims
- 0597US9765143B2Methods for manipulating phagocytosis mediated by CD47UNIV LELAND STANFORD JUNIOR·Filed 2017·Granted Sep 19, 2017·17 cites·10 claims
- 0697US9624305B2Methods of manipulating phagocytosis mediated by CD47UNIV LELAND STANFORD JUNIOR·Filed 2016·Granted Apr 18, 2017·17 cites·3 claims
- 0797US9611329B2Methods of manipulating phagocytosis mediated by CD47UNIV LELAND STANFORD JUNIOR·Filed 2016·Granted Apr 4, 2017·19 cites·3 claims
- 0897US9605076B2Methods of manipulating phagocytosis mediated by CD47UNIV LELAND STANFORD JUNIOR·Filed 2016·Granted Mar 28, 2017·19 cites·3 claims
- 0996US11141480B2Dosing parameters for CD47 targeting therapies to hematologic malignanciesUNIV LELAND STANFORD JUNIOR·Filed 2018·Granted Oct 12, 2021·9 cites·6 claims
- 1096US8758750B2Synergistic anti-CD47 therapy for hematologic cancersWEISSMAN IRVING L·Filed 2010·Granted Jun 24, 2014·50 cites·8 claims
- 1196US8562997B2Methods of treating acute myeloid leukemia by blocking CD47JAISWAL SIDDHARTHA·Filed 2010·Granted Oct 22, 2013·93 cites·2 claims
- 1294US2025333502A1Methods for Manipulating Phagocytosis Mediated by CD47UNIV LELAND STANFORD JUNIOR·Filed 2024·Application pending·0 cites
- 1385US12194093B2Dosing parameters for CD47 targeting therapies to hematologic malignanciesUNIV LELAND STANFORD JUNIOR·Filed 2023·Granted Jan 14, 2025·0 cites·6 claims
- 1484US2022267439A1Methods for Manipulating Phagocytosis Mediated by CD47UNIV LELAND STANFORD JUNIOR·Filed 2022·Application pending·0 cites
- 1581US12162939B2Methods for manipulating phagocytosis mediated by CD47UNIV LELAND STANFORD JUNIOR·Filed 2021·Granted Dec 10, 2024·0 cites·4 claims
- 1681US11780918B2Markers of acute myeloid leukemia stem cellsUNIV LELAND STANFORD JUNIOR·Filed 2022·Granted Oct 10, 2023·0 cites·16 claims
- 1780US11718670B2Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancerUNIV LELAND STANFORD JUNIOR·Filed 2022·Granted Aug 8, 2023·0 cites·14 claims
- 1880US2025066473A1Treatment of cancer with combinations of immunoregulatory agentsUNIV LELAND STANFORD JUNIOR·Filed 2024·Application pending·0 cites
- 1979US2023406923A1Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancerUNIV LELAND STANFORD JUNIOR·Filed 2023·Application pending·0 cites
- 2077US12274746B2Dosing parameters for CD47 targeting therapies to hematologic malignanciesUNIV LELAND STANFORD JUNIOR·Filed 2021·Granted Apr 15, 2025·0 cites·11 claims
- 2177US11891450B2Anti-CD47 agent-based treatment of CD20-positive cancerFORTY SEVEN INC·Filed 2019·Granted Feb 6, 2024·1 cites·20 claims
- 2273US2024218077A1Anti-cd47 agent-based treatment of cd20-positive cancerFORTY SEVEN INC·Filed 2023·Application pending·0 cites
- 2373US2019233515A1Methods for Manipulating Phagocytosis Mediated by CD47UNIV LELAND STANFORD JUNIOR·Filed 2019·Application pending·0 cites
- 2472US2024150461A1Anti-cd47 agent-based ovarian cancer therapyFORTY SEVEN INC·Filed 2023·Application pending·0 cites
- 2571US2021214437A1Synergistic anti-cd47 therapy for hematologic cancersUNIV LELAND STANFORD JUNIOR·Filed 2021·Application pending·0 cites
- 2670US10640561B2Methods for manipulating phagocytosis mediated by CD47UNIV LELAND STANFORD JUNIOR·Filed 2017·Granted May 5, 2020·0 cites·4 claims
- 2767US2024124578A1Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemiaFORTY SEVEN INC·Filed 2023·Application pending·0 cites
- 2867US2014161825A1Methods of Treating Acute Myeloid Leukemia by Blocking CD47UNIV LELAND STANFORD JUNIOR·Filed 2013·Application pending·0 cites
- 2967US2014065169A1Methods of Treating Acute Myeloid Leukemia by Blocking CD47UNIV LELAND STANFORD JUNIOR·Filed 2013·Application pending·0 cites
- 3066US2021230276A1Treatment of cancer with combinations of immunoregulatory agentsUNIV LELAND STANFORD JUNIOR·Filed 2021·Application pending·0 cites
- 3162US11802153B2Anti-CD47 agent-based ovarian cancer therapyFORTY SEVEN INC·Filed 2018·Granted Oct 31, 2023·0 cites·17 claims
- 3262US11472878B2Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancerUNIV LELAND STANFORD JUNIOR·Filed 2017·Granted Oct 18, 2022·0 cites·10 claims
- 3362US2023365682A1Combination therapy for treating colorectal cancerGILEAD SCIENCES INC·Filed 2023·Application pending·0 cites
- 3461US2014369924A1Synergistic anti-cd47 therapy for hematologic cancersUNIV LELAND STANFORD JUNIOR·Filed 2014·Application pending·0 cites
- 3560US11795223B2Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemiaFORTY SEVEN INC·Filed 2020·Granted Oct 24, 2023·0 cites·12 claims
- 3660US2019048075A1Synergistic anti-cd47 therapy for hematologic cancersUNIV LELAND STANFORD JUNIOR·Filed 2018·Application pending·0 cites
- 3759US10942185B2Therapeutic and diagnostic methods for manipulating phagocytosis through calreticulin and low density lipoprotein-related receptorUNIV LELAND STANFORD JUNIOR·Filed 2016·Granted Mar 9, 2021·0 cites·4 claims
- 3859US2023355796A1Combination therapy for treating trop-2 expressing cancersGILEAD SCIENCES INC·Filed 2023·Application pending·0 cites
- 3956US2023014026A1Anti-Tumor Combination Therapy comprising Anti-CD19 Antibody and Polypeptides Blocking the SIRPalpha-CD47 Innate Immune CheckpointMORPHOSYS AG·Filed 2021·Application pending·0 cites
- 4056US2022340679A1CO-INHIBITION OF CD47/SIRPalpha BINDING AND NEDD8-ACTIVATING ENZYME E1 REGULATORY SUBUNIT FOR THE TREATMENT OF CANCERGILEAD SCIENCES INC·Filed 2022·Application pending·0 cites
- 4150US2021147568A1Anti-cd47 based treatment of blood cancerFORTY SEVEN INC·Filed 2020·Application pending·0 cites
- 4250US2017210803A1Treatment of cancer with combinations of immunoregulatory agentsUNIV LELAND STANFORD JUNIOR·Filed 2017·Application pending·0 cites
- 4349US2014271683A1Therapeutic and Diagnostic Methods for Manipulating Phagocytosis Through Calreticulin and Low Density Lipoprotein-Related ReceptorCHAO MARK P·Filed 2011·Application pending·0 cites
- 4444US2021047416A1Treatment of ovarian cancer with anti-cd47 and anti-pd-l1FORTY SEVEN INC·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mark P. Chao files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →